Latiglutenase (ALV003 / BL-7010) (Investigational)
Treatment for Celiac Disease
Typical Dosage: 300 mg before meals
Effectiveness
55%
Safety Score
80%
Clinical Trials
8
Participants
1.5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
80
DangerousModerateSafe
Treatment Details
Dosage Range
300 mg before meals
Time to Effect
With meals
Treatment Duration
Long-term, with meals
Evidence Quality
MODERATENumber Needed to Treat (NNT)
9(Treat 9 patients to see 1 additional successful outcome)
Confidence Score
60%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$4,500
Monitoring:$100
Side Effect Mgmt:$50
Total Annual:$4,650
Cost-Effectiveness Analysis
QALYs Gained
0.15
Outcome-Based Costs
Cost per Responder
$13,285
Prescription Access Economics
Latiglutenase (ALV003 / BL-7010) (Investigational) Outcomes
for Celiac Disease
Efficacy Outcomes
Overall Effectiveness
+55%
Response Rate
+35%
Common Side Effects
Abdominal pain
+12%
Flatulence
+10%
Nausea
+5%
Sources:
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov